Business Development

By exploiting a novel therapeutic target, our vision is to develop novel single agent & combinatorial cancer treatments with the potential to address serious unmet patient needs.

As APIM Therapeutics further develops its lead drug candidate ATX-101 for various cancer indications, we seek research collaboration and/or partnering opportunities to maximize the value of our technology.

For questions or inquiries regarding collaborations and partnering, please contact:

Kostas Alevizopoulos PhD.
Chief Executive Officer
+47 73 49 4002
This email address is being protected from spambots. You need JavaScript enabled to view it.